IP Library Granted Patent US 11,154,568
Granted Patent B2
US 11,154,568 · App. 16/646,854 · Granted Oct 26, 2021

Composition for relieving hangover or composition for preventing, alleviating or treating alcoholic liver disease, comprising b-glucan as active ingredient

Inventors: Jong Dae Lee (Seoul, KR); Sung Hong Kim (Seoul, KR); Young Kyun Kim (Bhcheon-si, KR); Je Kyoung Kim (Bucheon-si, KR); Yong Man Jang (Siheung-si, KR); Min Ji Kim (Donghae-si, KR); Eun Ji Park (Gwangju, KR); Chul Su Yang (Ansan-si, KR)
Assignee: QUEGEN BIOTECH CO., LTD.
A61K31/716A23L2/52A23L31/00A23L33/125A23L33/40A61P1/16A61P25/32A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,154,568
App. No.
16/646,854
Granted
Oct 26, 2021
Kind
B2
Abstract

The present invention relates to a composition for relieving a hangover or a composition for preventing, alleviating or treating alcoholic liver disease, comprising a β-glucan as an active ingredient.

Claims (2)

1. A method for relieving a hangover, comprising orally administering an effective amount of R-(1,6)-branched (1,3)-glucan isolated from Schizophyllum commune or a culture thereof to a subject in need thereof, wherein the effective amount is obtained when administration of the β-(1,6)-branched (1,3)-glucan suppresses a side effect caused by the hangover, wherein the side effect is body weight gain and/or increased blood triglyceride levels.

2. The method of claim 1 , wherein the β-(1,6)-branched (1,3)-glucan is contained in a composition at 0.001 to 50 wt % with respect to the total weight of the composition.

Assignments (2)
CHANGE OF NAME Recorded Oct 14, 2025
From: QUEGEN BIOTECH CO., LTD.
To: BETA BIO CORPORATION
Reel/Frame 073064/0583 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2020
From: LEE, JONG DAE; KIM, SUNG HONG; KIM, JE KYOUNG; JANG, YONG MAN; KIM, MIN JI; PARK, EUN JI; YANG, CHUL SU; KIM, YOUNG KYUN
To: QUEGEN BIOTECH CO., LTD.
Reel/Frame 052112/0950 →
Priority Claims (2)
KR 10-2017-0120339 · Sep 19, 2017 · national
KR 10-2018-0101390 · Aug 28, 2018 · national
Continuity (1)
Related Publication 20210008094A1 · Jan 14, 2021